The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.<\/p>
<\/p>
<\/strong><\/p> <\/p> A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.<\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-27T16:52:12.8962611Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-22", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cystic Fibrosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4243", "label" : {"_value" : "Biography information for Dan Jarvis"}
}
, "tablingMemberConstituency" : {"_value" : "Barnsley Central"}
, "tablingMemberPrinted" : [{"_value" : "Dan Jarvis"}
], "uin" : "211584"}
, {"_about" : "http://data.parliament.uk/resources/99859", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/99859/answer", "answerText" : {"_value" : " We are committed to ensuring National Health Service patients have access to effective medicines on terms that represent value to the NHS and taxpayers and that patients, are supported to get the best outcomes from their medicines.<\/p> <\/p> <\/p> <\/p> The Department, in collaboration with NHS England, has recently commissioned an independent evaluation of Innovation Health and Wealth. Jointly led by the University of Manchester and RAND Europe, The first initial phase is now underway, the study is expected to take three years to complete.<\/p> <\/p> <\/em><\/p> <\/p> In addition, NHS England, with the Health and Social Care Information Centre publishes an innovation scorecard which represents the rate of uptake and utility of medicines in both primary and secondary care, on a regular basis. This publication sets out levels of uptake and utility for National Institute for Health and Care Excellence appraised medicines and technologies, and evidence suggests that steady growth is being achieved and the most recent information is available at:<\/p> <\/p> <\/p> <\/p> www.hscic.gov.uk/searchcatalogue?productid=15598&q=innovation+scorecard&sort=Relevance&size=10&page=1#top<\/a><\/p> <\/p> <\/strong><\/p> <\/p> Earlier this year, NHS England also undertook an extensive consultation to \u2018refresh\u2019 the Innovation Health and Wealth policy framework and we understand that recommendations from this will be included in NHS England's five year Forward Look.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-23T16:35:13.9262134Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescription Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if his Department will commission a review of the innovation, evaluation and adoption of new medicines in the NHS; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "211101"}
, {"_about" : "http://data.parliament.uk/resources/99878", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/99878/answer", "answerText" : {"_value" : " Information on spend by the National Health Service in primary and secondary care is in the table.<\/p> <\/p> <\/strong><\/p> <\/p> Medicines for the treatment of hepatitis C have been defined as all medicines contained within British National Formulary section 5.3.3.4 - chronic hepatitis C. In addition, peginterferon alfa, ribavirin and interferon alfa have also been included as they have been recommended in National Institute for Health and Care excellence technology appraisals for use in treating hepatitis C.<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed and therefore figures may include costs from prescriptions of these drugs other than for hepatitis C.<\/p> <\/p> <\/strong><\/p> <\/p> This is the cost of the medicines at NHS list price and not necessarily the price paid. It does not take account of discounts, dispensing costs, fees or prescription charges income.<\/p> <\/p> <\/p> <\/p> <\/p> <\/p> Financial Year<\/p><\/td> Cost (£000)<\/p><\/td><\/tr> 2011-12<\/p><\/td> 34,198.9<\/p><\/td><\/tr> 2012-13<\/p><\/td> 52,709.2<\/p><\/td><\/tr> 2013-14<\/p><\/td> 72,122.0<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p> Source: <\/em><\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-23T16:40:20.5892873Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-20", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hepatitis: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much his Department spent on medicines for hepatitis C treatment in each of the last three financial years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
, "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
], "uin" : "211146"}
, {"_about" : "http://data.parliament.uk/resources/93839", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/93839/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) has published clinical guidelines on a range of mental health topics, such as depression, anxiety and schizophrenia. Clinical guidelines provide guidance on the treatment of patients across the care pathway and each guideline recommends a number of treatments. <\/p> Appraisal Number<\/p><\/td> Year<\/p><\/td> Technology<\/p><\/td> Condition<\/p><\/td> Categorisation<\/p><\/td><\/tr> TA59<\/p><\/td> 2003<\/p><\/td> Electroconvulsive therapy<\/p><\/td> Catatonia/ prolonged or severe manic episode<\/p><\/td> Optimised1<\/sup><\/p><\/td><\/tr> TA098<\/p><\/td> 2006<\/p><\/td> Atomoxetine<\/p><\/td> Attention deficit hyperactivity disorder (ADHD)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA098<\/p><\/td> 2006<\/p><\/td> Dexamfetamine<\/p><\/td> Attention deficit hyperactivity disorder (ADHD)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA098<\/p><\/td> 2006<\/p><\/td> Methylphenidate<\/p><\/td> Attention deficit hyperactivity disorder (ADHD)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA213<\/p><\/td> 2011<\/p><\/td> Aripiprazole<\/p><\/td> Schizophrenia in people aged 15-17 years<\/p><\/td> Recommended<\/p><\/td><\/tr> TA217<\/p><\/td> 2011<\/p><\/td> Donepezil<\/p><\/td> Alzheimer's disease (mild to moderate)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA217<\/p><\/td> 2011<\/p><\/td> Galantamine<\/p><\/td> Alzheimer's disease (mild to moderate)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA217<\/p><\/td> 2011<\/p><\/td> Rivastigmine<\/p><\/td> Alzheimer's disease (mild to moderate)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA217<\/p><\/td> 2011<\/p><\/td> Memantine<\/p><\/td> Alzheimer's disease (moderate)<\/p><\/td> Optimised<\/p><\/td><\/tr> TA217<\/p><\/td> 2011<\/p><\/td> Memantine<\/p><\/td> Alzheimer's disease (severe)<\/p><\/td> Recommended<\/p><\/td><\/tr> TA292<\/p><\/td> 2013<\/p><\/td> Aripiprazole<\/p><\/td> Moderate to severe manic episodes in adolescents with bipolar disorder<\/p><\/td> Recommended<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p>
Additionally, the following technologies for the treatment of mental health and behavioural conditions are recommended by NICE technology appraisal guidance:<\/p>